Atrial fibrillation is associated with a marker of endothelial function and oxidative stress in patients with acute myocardial infarction

PLoS ONE

Volumn 10, Issue 7, 2015, Pages

  Stamboul, Karim ^a   Lorin, Julie ^b   Lorgis, Luc ^a   Guenancia, Charles ^a   Beer, Jean Claude ^a   Touzery, Claude ^a   Rochette, Luc ^b   Vergely, Catherine ^b   Cottin, Yves ^a   Zeller, Marianne ^b  

^a DIJON UNIVERSITY HOSPITAL   (France)

^b UNIVERSITÉ DE BOURGOGNE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

6 N,N' DIMETHYLARGININE; ACETYLSALICYLIC ACID; AMIODARONE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; N(G),N(G) DIMETHYLARGININE; ARGININE; BIOLOGICAL MARKER; N,N-DIMETHYLARGININE;

ACUTE HEART FAILURE; ACUTE HEART INFARCTION; ADULT; AGE; AGED; ARTICLE; ATRIAL FIBRILLATION; BLOOD SAMPLING; CEREBROVASCULAR ACCIDENT; DISEASE ASSOCIATION; ECHOCARDIOGRAPHY; ELECTROCARDIOGRAPHY MONITORING; ENDOTHELIAL DYSFUNCTION; FEMALE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART RATE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HOSPITAL ADMISSION; HOSPITALIZATION; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; OBSERVATIONAL STUDY; OXIDATIVE STRESS; PATHOGENESIS; ANALOGS AND DERIVATIVES; BLOOD; ELECTROCARDIOGRAPHY; ENDOTHELIUM; HEART INFARCTION; MIDDLE AGED; MULTIVARIATE ANALYSIS; PATHOPHYSIOLOGY; PROCEDURES; RISK ASSESSMENT; RISK FACTOR; STATISTICAL MODEL; STATISTICS AND NUMERICAL DATA; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ARGININE; ATRIAL FIBRILLATION; BIOMARKERS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; ELECTROCARDIOGRAPHY; ENDOTHELIUM; FEMALE; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; MYOCARDIAL INFARCTION; OXIDATIVE STRESS; RISK ASSESSMENT; RISK FACTORS;

EID: 84941283144     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0131439     Document Type: Article

References (39)

1. Rahman F, Kwan GF, Benjamin EJ. Global epidemiology of atrial fibrillation. Nat Rev. Cardiol. 2014;11:639-654.
2. Jabre P, Jouven X, Adnet F, Thabut G, Bielinski SJ, Weston SA et al. Atrial fibrillation and death after myocardial infarction: A community study. Circulation. 2011;123:2094-2100.
3. Schmitt J, Duray G, Gersh BJ, Hohnloser SH. Atrial fibrillation in acute myocardial infarction: A systematic review of the incidence, clinical features and prognostic implications. Eur Heart J. 2009;30:1038-1045.
4. Stamboul K, Zeller M, Fauchier L, Gudjoncik A, Buffet P, Garnier F et al. Incidence and prognostic significance of silent atrial fibrillation in acute myocardial infarction. Int J Cardiol. 2014;174:611-617.
5. Saczynski JS, McManus D, Zhou Z, Spencer F, Yarzebski J, Lessard D et al. Trends in atrial fibrillation complicating acute myocardial infarction. Am J cardiol. 2009;104:169-174.
6. Polovina MM, Lip GY, Potpara TS. Endothelial (dys) function in lone atrial fibrillation. Curr Pharm Des. 2014.
7. Rochette L, Lorin J, Zeller M, Guilland JC, Lorgis L, Cottin Y et al. Nitric oxide synthase inhibition and oxidative stress in cardiovascular diseases: Possible therapeutic targets? Pharmacol Ther. 2013;140:239-257.
8. Boger RH. Asymmetric dimethylarginine (adma): A novel risk marker in cardiovascular medicine and beyond. Ann Med. 2006;38:126-136.
9. Sibal L, Agarwal SC, Home PD, Boger RH. The role of asymmetric dimethylarginine (adma) in endothelial dysfunction and cardiovascular disease. Curr Cardiol Rev. 2010;6:82-90.
10. Closs EI, Basha FZ, Habermeier A, Forstermann U. Interference of l-arginine analogues with l-arginine transport mediated by the y+ carrier hcat-2b. Nitric oxide. 1997;1:65-73.
11. Stuhlinger MC, Oka RK, Graf EE, Schmolzer I, Upson BM, Kapoor O et al. Endothelial dysfunction induced by hyperhomocyst (e) inemia: Role of asymmetric dimethylarginine. Circulation. 2003;108:933-938.
12. Kielstein JT, Impraim B, Simmel S, Bode-Boger SM, Tsikas D, Frolich JC et al. Cardiovascular effects of systemic nitric oxide synthase inhibition with asymmetrical dimethylarginine in humans. Circulation. 2004;109:172-177.
13. Achan V, Broadhead M, Malaki M, Whitley G, Leiper J, MacAllister R et al. Asymmetric dimethylarginine causes hypertension and cardiac dysfunction in humans and is actively metabolized by dimethylarginine dimethylaminohydrolase. Arterioscler Thromb Vasc Biol. 2003;23:1455-1459.
14. Suda O, Tsutsui M, Morishita T, Tasaki H, Ueno S, Nakata S et al. Asymmetric dimethylarginine produces vascular lesions in endothelial nitric oxide synthase-deficient mice: Involvement of renin-angiotensin system and oxidative stress. Arterioscler Thromb Vasc Biol. 2004;24:1682-1688.
15. Schnabel R, Blankenberg S, Lubos E, Lackner KJ, Rupprecht HJ, Espinola-Klein C et al. Asymmetric dimethylarginine and the risk of cardiovascular events and death in patients with coronary artery disease: Results from the atherogene study. Circ Res. 2005;97:e53-59.
16. Zeller M, Korandji C, Guilland JC, Sicard P, Vergely C, Lorgis L et al. Impact of asymmetric dimethylarginine on mortality after acute myocardial infarction. Arterioscler Thromb Vasc Biol. 2008;28:954-960.
17. Cengel A, Sahinarslan A, Biberoglu G, Hasanoglu A, Tavil Y, Tulmac M et al. Asymmetrical dimethylarginine level in atrial fibrillation. Acta cardiol. 2008;63:33-37.
18. Goette A, Hammwohner M, Bukowska A, Scalera F, Martens-Lobenhoffer J, Dobrev D et al. The impact of rapid atrial pacing on adma and endothelial nos. Int J Cardiol. 2012;154:141-146.
19. Schulze F, Carter AM, Schwedhelm E, Ajjan R, Maas R, Von Holten RA et al. Symmetric dimethylarginine predicts all-cause mortality following ischemic stroke. Atherosclerosis. 2010;208:518-523.
20. Chao TF, Lu TM, Lin YJ, Tsao HM, Chang SL, Lo LW, et al. Plasma asymmetric dimethylarginine and adverse events in patients with atrial fibrillation referred for coronary angiogram. PloS one. 2013;8:e71675.
21. Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF 3rd, Feldman HI et al. A new equation to estimate glomerular filtration rate. Ann Inter Med. 2009;150:604-612.
22. Ivanova M, Artusi C, Boffa GM, Zaninotto M, Plebani M. HPLC determination of plasma dimethylarginines: Method validation and preliminary clinical application. Clin Chim Acta. 2010;411:1632-1636.
23. Lorin J, Guilland JC, Korandji C, Touzery C, Bichat F, Chagnon A et al. High levels of asymmetric dimethylarginine are strongly associated with low hdl in patients with acute myocardial infarction. PloS one. 2013;8:e64796.
24. Camm AJ, Kirchhof P, Lip GY, Schotten U, Savelieva I, Ernst S et al. Guidelines for the management of atrial fibrillation: The task force for the management of atrial fibrillation of the european society of cardiology (esc). Eur Heart J. 2010;31:2369-2429.
25. Schepers E, Glorieux G, Dhondt A, Leybaert L, Vanholder R. Role of symmetric dimethylarginine in vascular damage by increasing ros via store-operated calcium influx in monocytes. Nephrol Dial Transplant. 2009;24:1429-1435.
26. Schwedhelm E, Boger RH. The role of asymmetric and symmetric dimethylarginines in renal disease. Nat Rev Nephrol. 2011;7:275-285.
27. Xia W, Yin Z, Li J, Song Y, Qu X. Effects of rosuvastatin on asymmetric dimethylarginine levels and early atrial fibrillation recurrence after electrical cardioversion. Pacing Clin Electrophysiol. 2009;32:1562-1566.
28. Yang L, Xiufen Q, Shuqin S, Yang Y, Ying S, Yanwei Y et al. Asymmetric dimethylarginine concentration and recurrence of atrial tachyarrythmias after catheter ablation in patients with persistent atrial fibrillation. J Interv Card Electrophysiol. 2011;32:147-154.
29. Usui M, Matsuoka H, Miyazaki H, Ueda S, Okuda S, Imaizumi T. Increased endogenous nitric oxide synthase inhibitor in patients with congestive heart failure. Life Sci. 1998;62:2425-2430.
30. Zairis MN, Patsourakos NG, Tsiaousis GZ, Theodossis Georgilas A, Melidonis A, Makrygiannis SS et al. Plasma asymmetric dimethylarginine and mortality in patients with acute decompensation of chronic heart failure. Heart. 2012;98:860-864.
31. Duckelmann C, Mittermayer F, Haider DG, Altenberger J, Eichinger J, Wolzt M. Asymmetric dimethylarginine enhances cardiovascular risk prediction in patients with chronic heart failure. Arterioscl Thromb Vasc Biol. 2007;27:2037-2042.
32. Caplin B, Leiper J. Endogenous nitric oxide synthase inhibitors in the biology of disease: Markers, mediators, and regulators? Arterioscler Thromb Vasc Biol. 2012;32:1343-1353.
33. Von Leitner EC, Klinke A, Atzler D, Slocum JL, Lund N, Kielstein JT et al. Pathogenic cycle between the endogenous nitric oxide synthase inhibitor asymmetrical dimethylarginine and the leukocyte-derived hemoprotein myeloperoxidase. Circulation. 2011;124:2735-2745.
34. Antoniades C, Shirodaria C, Leeson P, Antonopoulos A, Warrick N, Van-Assche T et al. Association of plasma asymmetrical dimethylarginine (adma) with elevated vascular superoxide production and endothelial nitric oxide synthase uncoupling: Implications for endothelial function in human atherosclerosis. Eur Heart J. 2009;30:1142-1150.
35. Purohit A, Rokita AG, Guan X, Chen B, Koval OM, Voigt N et al. Oxidized ca (2+)/calmodulin-dependent protein kinase ii triggers atrial fibrillation. Circulation. 2013;128:1748-1757.
36. Youn JY, Zhang J, Zhang Y, Chen H, Liu D, Ping P et al. Oxidative stress in atrial fibrillation: An emerging role of NADPH oxidase. J Mol Cell Cardiol. 2013;62:72-79.
37. Cai H, Li Z, Goette A, Mera F, Honeycutt C, Feterik K, et al. Downregulation of endocardial nitric oxide synthase expression and nitric oxide production in atrial fibrillation: Potential mechanisms for atrial thrombosis and stroke. Circulation. 2002;106:2854-2858.
38. Liu H, Qu X, Liang Z, Chen W, Xia W, Song Y. Variance of DDAH/PRMT/ADMA pathway in atrial fibrillation dogs. Biochem Biophys Res Commun. 2008;377:884-888.
39. Wilson Tang WH, Tong W, Shrestha K, Wang Z, Levison BS, Delfraino B et al. Differential effects of arginine methylation on diastolic dysfunction and disease progression in patients with chronic systolic heart failure. Eur Heart J. 2008;29:2506-2513.